Skip to content

Study · Animal study (in vivo) · rat · 2026

8 results

Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.

Vahle B, Weidner S, Tomalka A, Schauer A, Augstein A, Männel A, Barthel P, Friedrich J, Beck G, Labeit S, Bowen TS, Siebert T, Linke A, Adams V

Circulation. Heart failure15 Jun 2026

PMID42290373 (opens in a new tab)DOI10.1161/circheartfailure.126.014397 (opens in a new tab)PepBankPUB-42290373
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In HFpEF rats, elamipretide improved whole-muscle contractile function of the soleus versus NaCl.

    In plain wordsIn rats with a heart failure model, elamipretide improved the force of the soleus muscle compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseWhole-muscle contractile function, soleus
    Study

    ratn = 24

    Female ZSF1 obese rat model of HFpEF
    Comparator
    NaCl
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (rat).

    Measurements

    Whole-muscle contractile function change
    8.2%
    soleus

    Source sentences

    Summary
    whole muscle (soleus: +8.2%, P=0.041
    2 context sentences
    Summary · context
    Female zucker fatty spontaneously hypertensive heart failure F1 hybrid lean (n=10, control) and obese rats (n=24, HFpEF) were included.
    Summary · context
    At 20 weeks of age, HFpEF rats were randomized into 2 groups receiving NaCl (n=12) or Elamipretide (n=12) for 12 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In HFpEF rats, elamipretide improved whole-muscle contractile function of the extensor digitorum longus versus NaCl.

    In plain wordsIn rats with a heart failure model, elamipretide improved the force of the extensor digitorum longus muscle compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseWhole-muscle contractile function, extensor digitorum longus
    Study

    ratn = 24

    Female ZSF1 obese rat model of HFpEF
    Comparator
    NaCl
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (rat).

    Measurements

    Whole-muscle contractile function change
    10.9%
    extensor digitorum longus

    Source sentences

    Summary
    extensor digitorum longus: +10.9%, P=0.016
    2 context sentences
    Summary · context
    Female zucker fatty spontaneously hypertensive heart failure F1 hybrid lean (n=10, control) and obese rats (n=24, HFpEF) were included.
    Summary · context
    At 20 weeks of age, HFpEF rats were randomized into 2 groups receiving NaCl (n=12) or Elamipretide (n=12) for 12 weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In HFpEF rats, elamipretide improved single-fiber contractile function of the soleus versus NaCl.

    In plain wordsIn rats with a heart failure model, elamipretide improved single muscle fibre force in the soleus compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSingle-fiber contractile function, soleus
    Study

    ratn = 24

    Female ZSF1 obese rat model of HFpEF
    Comparator
    NaCl
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (rat).

    Measurements

    Single-fiber contractile function change
    173.2%
    soleus

    Source sentences

    Summary
    single-fiber (soleus: +173.2%, P<0.001
    2 context sentences
    Summary · context
    Female zucker fatty spontaneously hypertensive heart failure F1 hybrid lean (n=10, control) and obese rats (n=24, HFpEF) were included.
    Summary · context
    At 20 weeks of age, HFpEF rats were randomized into 2 groups receiving NaCl (n=12) or Elamipretide (n=12) for 12 weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In HFpEF rats, the change in single-fiber contractile function of the extensor digitorum longus with elamipretide was not significant (P=ns).

    In plain wordsIn rats with a heart failure model, elamipretide did not significantly change single muscle fibre force in the extensor digitorum longus.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeSingle-fiber contractile function, extensor digitorum longus
    Study

    ratn = 24

    Female ZSF1 obese rat model of HFpEF
    Comparator
    NaCl
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (rat).

    Measurements

    Single-fiber contractile function change
    66%
    extensor digitorum longus

    Source sentences

    Summary
    extensor digitorum longus: +66.0%, P=ns
    2 context sentences
    Summary · context
    Female zucker fatty spontaneously hypertensive heart failure F1 hybrid lean (n=10, control) and obese rats (n=24, HFpEF) were included.
    Summary · context
    At 20 weeks of age, HFpEF rats were randomized into 2 groups receiving NaCl (n=12) or Elamipretide (n=12) for 12 weeks.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In HFpEF rats, elamipretide reduced titin phosphorylation in the soleus versus NaCl.

    In plain wordsIn rats with a heart failure model, elamipretide lowered titin phosphorylation in the soleus muscle compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseTitin phosphorylation, soleus
    Study

    ratn = 24

    Female ZSF1 obese rat model of HFpEF
    Comparator
    NaCl
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (rat).

    Measurements

    Titin phosphorylation change
    −35.4%
    soleus

    Source sentences

    Summary
    titin phosphorylation (soleus: -35.4%, P<0.001
    2 context sentences
    Summary · context
    Female zucker fatty spontaneously hypertensive heart failure F1 hybrid lean (n=10, control) and obese rats (n=24, HFpEF) were included.
    Summary · context
    At 20 weeks of age, HFpEF rats were randomized into 2 groups receiving NaCl (n=12) or Elamipretide (n=12) for 12 weeks.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In HFpEF rats, elamipretide reduced titin phosphorylation in the extensor digitorum longus versus NaCl.

    In plain wordsIn rats with a heart failure model, elamipretide lowered titin phosphorylation in the extensor digitorum longus muscle compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseTitin phosphorylation, extensor digitorum longus
    Study

    ratn = 24

    Female ZSF1 obese rat model of HFpEF
    Comparator
    NaCl
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (rat).

    Measurements

    Titin phosphorylation change
    −40.2%
    extensor digitorum longus

    Source sentences

    Summary
    extensor digitorum longus: -40.2%, P<0.001
    2 context sentences
    Summary · context
    Female zucker fatty spontaneously hypertensive heart failure F1 hybrid lean (n=10, control) and obese rats (n=24, HFpEF) were included.
    Summary · context
    At 20 weeks of age, HFpEF rats were randomized into 2 groups receiving NaCl (n=12) or Elamipretide (n=12) for 12 weeks.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In HFpEF rats, elamipretide prevented the development of fiber atrophy in the soleus versus NaCl.

    In plain wordsIn rats with a heart failure model, elamipretide prevented muscle fibre shrinkage in the soleus compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMuscle atrophy development, soleus
    Study

    ratn = 24

    Female ZSF1 obese rat model of HFpEF
    Comparator
    NaCl
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (rat).

    Measurements

    Atrophy prevention
    49%
    soleus

    Source sentences

    Summary
    preventing atrophy development (soleus: +49%, P=0.001
    2 context sentences
    Summary · context
    Female zucker fatty spontaneously hypertensive heart failure F1 hybrid lean (n=10, control) and obese rats (n=24, HFpEF) were included.
    Summary · context
    At 20 weeks of age, HFpEF rats were randomized into 2 groups receiving NaCl (n=12) or Elamipretide (n=12) for 12 weeks.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In HFpEF rats, elamipretide prevented the development of fiber atrophy in the extensor digitorum longus versus NaCl.

    In plain wordsIn rats with a heart failure model, elamipretide prevented muscle fibre shrinkage in the extensor digitorum longus compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMuscle atrophy development, extensor digitorum longus
    Study

    ratn = 24

    Female ZSF1 obese rat model of HFpEF
    Comparator
    NaCl
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (rat).

    Measurements

    Atrophy prevention
    54.8%
    extensor digitorum longus

    Source sentences

    Summary
    extensor digitorum longus: +54.8%, P<0.001
    2 context sentences
    Summary · context
    Female zucker fatty spontaneously hypertensive heart failure F1 hybrid lean (n=10, control) and obese rats (n=24, HFpEF) were included.
    Summary · context
    At 20 weeks of age, HFpEF rats were randomized into 2 groups receiving NaCl (n=12) or Elamipretide (n=12) for 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.